THE GLYCEMIC OUTCOMES OF THE EVERSENSE CGM SYSTEM IN AN EXPANDED COHORT OF 582 REAL-WORLD US COMMERCIAL USERS
- Katherine S. Tweden, United States of America
- Samanwoy Ghosh-dastidar, United States of America
- Patricia Sanchez, United States of America
- Katherine S. Tweden, United States of America
- Francine Kaufman, United States of America
Abstract
Background and Aims
The first long term implantable Eversense CGM system was approved for US commercialization in 2018. Accuracy and safety have been demonstrated in multiple clinical trials and real-world studies. The first US real-world data publication reported on 205 users with a 90-day sensor wear cycle. Using the same analytic methodology, a larger user base of 582 was subsequently analyzed.
Methods
De‐identified sensor glucose (SG) data from the Eversense data management system were analyzed for the first 582 patients who reached a 90‐day wear period and compared to the first 205 patients previously reported. Mean SG, variability measures (SD, CV), GMI, and glucometrics were computed. Median transmitter wear time was assessed.
Results
The makeup of the 582 cohort was similar to the 205 cohort with ~1/3 naïve CGM users and ~80-85% T1D. Glucometric data were similar between the larger cohort and the original population (Table). The mean SG was 162 and 161 mg/dL, CV was .35, GMI was 7.18% and 7.16%, and time in range was 62 and 63% in the 205 and 582 user groups, respectively. Mean percent SG <70mg/dL approached the targeted value of <4% (4.2 and 4.0%). Median transmitter wear time was 84 and 85%.
Conclusions
These data show that the promising glycemic outcomes and system usage obtained in the first 205 users was sustained in a larger cohort of US commercial Eversense CGM system users and likely represents the real-world population outcomes to be expected when using the system as a tool for diabetes management.